



FOR IMMEDIATE RELEASE

Media Contact:

TetraLogic Pharmaceuticals
James Goldschmidt, Ph.D.
610-889-9900

Rx Communications Group, LLC
Eric Goldman
917-322-2563
egoldman@rxir.com

TetraLogic Pharmaceuticals Founder John Gill Receives Semper Fidelis Award

MALVERN, Pa., April 23, 2012 – John M. Gill, TetraLogic Pharmaceuticals’ President and Chief Executive Officer, received the prestigious annual Semper Fidelis Award which is presented each year to an outstanding American who has maintained faithfulness to the three Corps Values of Honor, Courage, and Commitment to the Marine Corps itself, patriotic duty to the United States of America, and allegiance and dedication to his or her community. Gill, a former United States Marine, was presented the Semper Fidelis (Latin for “always faithful”) at the Philadelphia Marine Corps Scholarship Foundation Ball on April 20th.

“I am both humbled and honored as this award holds great significance to me,” said Gill. “The most meaningful influences in my life have been my family, which includes several former Marines, my Marine experience as the turning point of my life and my subsequent commitment to education and doing things that I hope will make a difference. I am proud to be part of a scholarship foundation dedicated to providing educational opportunities to the children of the United States Marines and Navy Corpsmen.”

About The Marine Corps Scholarship Foundation

The Marine Corps Scholarship Foundation is the nation’s oldest and largest provider of need-based scholarships to children of Marines and Navy Corpsmen, with particular attention given to those whose parent has been killed or wounded in combat, or who have demonstrated financial need. Additional information is available on the foundation’s Web site at www.mscf.org.

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company’s institutional investors include Clarus Ventures, HealthCare Ventures, Quaker Partners, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company’s Web site at www.tetralogicpharma.com.

###